Skip to content

Science News About Treatments

Designer Agent Blocks Pain in Mice Without Morphine’s Side Effects

Science Update

Scientists have synthesized a molecule with a unique profile of highly specific pain-relieving properties and demonstrated its efficacy in mice.

Continue Reading

Electroconvulsive Therapy Lifts Depression, Sustains Remission in Older Adults

Science Update

An individualized program of follow-up treatment with electroconvulsive therapy (ECT) combined with an antidepressant was effective in preventing relapse in patients 60 years and older who had had a successful initial course of treatment for severe depression.

Continue Reading

Ketamine Lifts Depression via a Byproduct of its Metabolism

Press Release

A chemical byproduct, or metabolite, created as the body breaks down likely holds the secret to its rapid antidepressant action .

Continue Reading

Facebook Q&A on Electroconvulsive Therapy

Science Update

On March 17, 2016, NIMH hosts a Facebook Q&A on electroconvulsive therapy with expert Dr. Sarah Lisanby.

Continue Reading

A BRIGHT Technological Future for Mental Health Trials

Science Update

Is mobile mental health research the next frontier for smartphones? Based on Dr. Patricia Areán’s pioneering BRIGHTEN study, research via smartphone app is already a reality.

Continue Reading

Team-based Treatment for First Episode Psychosis Found to be High Value

Press Release

Coordinated Specialty Care for First Episode Psychosis is Cost Effective

Continue Reading

Federal Agencies Partner to Promote Coordinated Services for Patients with First Episode Psychosis

Science Update

On October 16, the Centers for Medicare and Medicaid Services announced support for a new treatment for first episode psychosis called coordinated specialty care (CSC). This decision means more clinics may be able to offer CSC and it may become more readily available.

Continue Reading

Antipsychotics Use Among Older Adults Increases with Age

Press Release

Researchers find antipsychotic use among older adults increases with age despite known health risks. In 2010, more than 3/4 of seniors receiving an antipsychotic prescription had no documented clinical psychiatric diagnosis during the year. In addition, among those who did have a diagnosed mental disorder and/or dementia, nearly half of the oldest patients had dementia, regardless of FDA warnings that antipsychotics increase mortality in people with dementia.

Continue Reading

Team-based Treatment is Better for First Episode Psychosis

Press Release

New research shows that a team-based, coordinated specialty care treatment plan produces better outcomes than typical community care for people with first episode psychosis. Investigators also found that treatment is most effective for people who receive care soon after psychotic symptoms begin.

Continue Reading

Embracing the SPIRIT of reducing suicide

Science Update

NIMH, NIH, and the National Institute of Justice are collaborating on a 4-year, $6.8 million study called Suicide Prevention for at-Risk Individuals in Transition or “SPIRIT.” The study focuses on the high-risk individuals who are transitioning from jail to community. SPIRIT is NIMH’s first major investment in suicide prevention in the justice system.

Continue Reading

Webinar Series – Office for Research on Disparities and Global Mental Health

Science Update

View the archived webinars with NIMH experts and grantees, which focus on training, research, and methodology

Continue Reading

Boys More Likely to Have Antipsychotics Prescribed, Regardless of Age

Press Release

Boys are more likely than girls to receive an antipsychotic prescription regardless of age, according to a new study published in JAMA Psychiatry.

Continue Reading

Medications for Patients with First Episode Psychosis May Not Meet Guidelines

Press Release

Many patients with first-episode psychosis receive medications that do not meet guidelines. A study finds that almost 40 % of people with first-episode psychosis in community mental health clinics across the country might benefit from medication treatment changes.

Continue Reading

Largest Autism Gene Dragnet Fingers 33 Prime Suspects

Science Update

Many patients with psychosis develop health risks associated with premature death early in the course of their mental illness, researchers have found.

Continue Reading

Rapid Agent Restores Pleasure-seeking Ahead of Other Antidepressant Action

Press Release

A drug being studied as a fast-acting mood-lifter restored pleasure-seeking behavior independent of – and ahead of – its other antidepressant effects.

Continue Reading

Groundbreaking Suicide Study

Science Update

A groundbreaking study will help researchers learn more about treating people with suicidal thoughts. Nearly 20,000 patients will be able to enroll in the trial. One of the treatments being tested was developed with the help of other patients

Continue Reading

Increased Health Risks Linked to First-episode Psychosis

Press Release

Many patients with psychosis develop health risks associated with premature death early in the course of their mental illness, researchers have found.

Continue Reading

NIMH Twitter Chat on Depression and the Development of Novel Medications

Science Update

NIMH Twitter Chat on Depression and the Development of Novel Medications

Continue Reading

For Schizophrenia, Newer Injectables Not Necessarily Better

Science Update

Treatment adherence is a problem among people with schizophrenia, who may not take medications because they don’t perceive its need or benefit, don’t like the side effects, or forget. To combat this issue, long-acting injectable medications are administered every 2-4 weeks. But are the new forms of these drugs better than the old ones?

Continue Reading

Jane Pearson Talks About Suicide Prevention Research on NPR’s Science Friday

Science Update

NIMH scientist Dr. Jane Pearson appeared on NPR’s Science Friday to discuss the latest findings in suicide prevention research.

Continue Reading

Webinar on Ketamine and Next Generation Therapies Featuring NIMH’s Carlos A. Zarate, M.D.

Science Update

On August 13, 2013, Carlos A. Zarate, M.D., from the National Institute of Mental Health will give a live presentation titled “Ketamine & Next Generation Therapies,” where he will discuss his research on novel medications for treatment-resistant depression and bipolar disorder at the Brain and Behavior Research Foundation.

Continue Reading

NAB Unveils Youth Mental Health Awareness Campaign

Science Update

On Tuesday, July 23, the National Association of Broadcasters (NAB) launched “OK2Talk,” a mental health awareness campaign to increase understanding and awareness about mental health in youth. The campaign includes television and radio ads in English and Spanish that feature teens and young adults opening up about their experiences with mental health.

Continue Reading

Community-based Treatments Offset Depression Disparities

Science Update

Improving care for depression in low-income communities -- places where such help is frequently unavailable or hard to find -- provides greater benefits to those in need when community groups such as churches and even barber shops help lead the planning process, according to a new study.

Continue Reading

Science/AAAS Webinar on Translational Neuroscience Research Featuring NIMH’s Carlos A. Zarate, M.D.

Science Update

Want to know how the latest findings in neuroscience research go from bench to bedside? NIMH and Science/AAAS partnered to produce an informative webinar on translating neurobiological research into treatments.

Continue Reading

HHS Secretary Kathleen Sebelius on the State of Mental Health Care in the United States

Science Update

HHS Secretary Kathleen Sebelius discusses state of U.S. mental health care, commemorates JFK’s speech on the topic 50 years ago.

Continue Reading